000590.SHE Tus Pharmaceutical Group Co Ltd
- Market cap
- CNY 1.85B
- P/E
- -
- P/B
- 3.54x
- ROE
- -6.1%
- Dividend yield
- 0.18%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 000590.SHE undervalued?
Graham numberThe Graham number of Tus Pharmaceutical Group Co Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Tus Pharmaceutical Group Co Ltd fundamental analysis
No fundamental analysis for Tus Pharmaceutical Group Co Ltd yet.
Tus Pharmaceutical Group Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Tus Pharmaceutical Group Co Ltd
Guhan Pharmaceutical Group Co., Ltd., together with its subsidiaries, manufactures and sells traditional Chinese medicines, chemical drugs, and health food under the Guhan brand in China. It operates through the Pharmaceutical and Health Product Manufacturing and Sales Business, Active Pharmaceutical Ingredient (API) Manufacturing and Sales Business, and Other Business segments. The company offers prescription and over-the-counter drugs, such as tonics, cardiovascular drugs,…
Full company profileTus Pharmaceutical Group Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Tus Pharmaceutical Group Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 301M | 293M | 186M | 315M | 275M | 301M | 351M | 405M | 343M | 338M | 293M |
| Gross Profit | 182M | 223M | 86.4M | 167M | 153M | 166M | 178M | 211M | 160M | 151M | 124M |
| Operating Income | 63.7M | 22.3M | -35.3M | 52.1M | 27.8M | 42.4M | 22.7M | 20.2M | -169M | -18.8M | -27.6M |
| EBITDA | 101M | 67.9M | -18.3M | 69.6M | 41.8M | 59.0M | 44.5M | 59.5M | -92.4M | -14.1M | -27.5M |
| Net Income | 55.2M | 19.2M | -38.2M | 42.4M | 22.7M | 35.4M | 18.1M | 25.2M | -125M | -50.5M | -31.8M |
| EPS | 0.25 | 0.08 | -0.16 | 0.18 | 0.09 | 0.15 | 0.08 | 0.11 | -0.52 | -0.21 | -0.13 |
| Balance Sheet | |||||||||||
| Total Assets | 631M | 874M | 817M | 847M | 892M | 968M | 1.17B | 1.15B | 1.01B | 889M | 876M |
| Total Liabilities | 367M | 290M | 237M | 225M | 247M | 286M | 464M | 423M | 412M | 340M | 351M |
| Shareholders' Equity | 261M | 583M | 580M | 622M | 645M | 680M | 698M | 724M | 598M | 548M | 524M |
| Cash & Short-term Investments | 123M | 124M | 321M | 314M | 343M | 326M | 261M | 190M | 177M | 178M | 98.4M |
| Total Debt | 78.3M | 20.0M | 38.0M | - | 5.00M | 8.58M | 134M | 83.1M | 84.5M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -32.5M | -89.1M | 654K | 29.2M | 51.5M | 25.2M | 54.5M | -28.4M | 17.4M | 29.0M | - |
| Capital Expenditure | 16.6M | 23.9M | 22.6M | 35.8M | 33.9M | 25.9M | 18.7M | 22.0M | 32.1M | 48.8M | 51.9M |
| Free Cash Flow | -49.1M | -113M | -21.9M | -6.63M | 17.6M | -679K | 35.8M | -51.4M | -14.7M | -19.8M | -92.7M |
| Ratios | |||||||||||
| ROE | 21.1% | 3.3% | -6.6% | 6.8% | 3.5% | 5.2% | 2.6% | 3.5% | -21.0% | -9.2% | -6.1% |
| ROA | 8.7% | 2.2% | -4.7% | 5.0% | 2.5% | 3.7% | 1.6% | 2.2% | -12.4% | -5.7% | -3.6% |
| Net Profit Margin | 18.3% | 6.5% | -20.5% | 13.5% | 8.3% | 11.8% | 5.2% | 6.2% | -36.6% | -15.0% | -10.8% |
| Debt to Equity | 0.30x | 0.03x | 0.07x | - | 0.01x | 0.01x | 0.19x | 0.11x | 0.14x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Tus Pharmaceutical Group Co Ltd dividends
- Dividend yield
- 0.18%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jun 21, 2013
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 3.35M | 0.01 | - |
| 2024 | CNY 3.47M | 0.01 | - |
| 2023 | CNY 4.20M | 0.02 | 16.6% |
| 2022 | CNY 338K | 0.00 | 1.9% |
| 2021 | CNY 62.8K | 0.00 | 0.2% |
| 2020 | CNY 139K | 0.00 | 0.6% |
| 2019 | CNY 1.38M | 0.01 | 3.3% |
| 2018 | CNY 1.38M | 0.01 | - |
| 2017 | CNY 1.11M | 0.00 | 5.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 11:10 on Sep 4, 2012.
Who owns Tus Pharmaceutical Group Co Ltd
- Insiders 53.58%
- Institutions 1.13%
- Public & others 45.29%
- Shares outstanding 239M
- Free float 124M
Tus Pharmaceutical Group Co Ltd company profile
- Company name
- Tus Pharmaceutical Group Co Ltd
- Ticker
- 000590.SHE
- ISIN
- CNE000000701
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Jan 5, 1996
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,064
- Fiscal year end
- December
- Address
- Headquarters Office Building, Hengyang, China, 421001
- Phone
- 86 73 4823 9332
- Website
- guhan.com
About Tus Pharmaceutical Group Co Ltd
Guhan Pharmaceutical Group Co., Ltd., together with its subsidiaries, manufactures and sells traditional Chinese medicines, chemical drugs, and health food under the Guhan brand in China. It operates through the Pharmaceutical and Health Product Manufacturing and Sales Business, Active Pharmaceutical Ingredient (API) Manufacturing and Sales Business, and Other Business segments. The company offers prescription and over-the-counter drugs, such as tonics, cardiovascular drugs, children's nutritional supplements, cold and flu remedies, and heat-clearing and detoxifying drugs. It also engages in nutrition and health consulting services; Chinese herbal medicine cultivation; medical research and experimental development; cultural and artistic exchange planning; medical consultation; internet sales; technology promotion, consulting, and agency services; outpatient services; and pharmaceutical wholesale and retail activities. The company was formerly known as Tus-Pharmaceutical Group Co., Ltd. and changed its name to Guhan Pharmaceutical Group Co., Ltd. in November 2025. Guhan Pharmaceutical Group Co., Ltd. was founded in 1956 and is headquartered in Hengyang, China.
Tus Pharmaceutical Group Co Ltd management
5- Ms. Ting TangVP, CFO & Non Independent Director · born 1978
- Mr. Lijun YanBoard Secretary · born 1971
- Mr. Ge WenVice President · born 1973
- Mr. Chengliang LiuVice President · born 1969
- Qian ZhuAccounting Supervisor